Titlebook: Diabetes - Perspectives in Drug Therapy; Mathias Schwanstecher Book 2011 Springer-Verlag Berlin Heidelberg 2011 antidiabetic therapy.diabe

華而不實(shí)

Protein-Based Materials in Cosmeticsretin-based therapies consist of two classes: (1) the injectable GLP-1 receptor agonists solely acting on the GLP-1 receptor and (2) dipeptidyl-peptidase inhibitors (DPP-4 inhibitors) as oral medications raising endogenous GLP-1 and other hormone levels by inhibiting the degrading enzyme DPP-4. In t

燒瓶

Narjes Rashidi,Maryam Tamaddon,Chaozong Liuchidonoylglycerol, are deeply involved in all aspects of the control of energy balance in mammals. While initially it was believed that this endocannabinoid signaling system would only facilitate energy intake, we now know that perhaps even more important functions of endocannabinoids and CB. recept

不能妥協(xié)

https://doi.org/10.1007/978-3-030-74723-7reby the early proximal tubule where secondary active transport of the sugar is mediated by the sodium-.-glucose cotransporter SGLT2. A model substance for the inhibitors is the O-glucoside phlorizin which inhibits transport competitively. Its binding to the transporter involves at least two differe

FOLLY

原來(lái)

Luz Fernanda Azuela,Rodrigo Vega-Ortegae into nicotinamide mononucleotide (NMN), an NAD intermediate. First identified in humans as a cytokine pre-B-cell colony enhancing factor (PBEF) and subsequently described as an insulin-mimetic hormone visfatin, Nampt has recently excited the scientific interest of researchers from diverse fields,

tooth-decay

AMOR

Matheus Alves Duarte da Silva,Marcos Cuetowide. Current interventions seem ineffective to halt this progression. With the failure of leptin as an anti-obesity therapeutic, ciliary neurotrophic factor (CNTF) has proven efficacious in models of obesity and leptin resistance, where leptin proved ineffective. CNTF is a gp130 ligand that has bee

小官

Jacket

ONYM

Takehiko Kariya,James E. Rosenbaumbetes due to the well-recognized role of excessive endogenous glucose production (EGP) in the hyperglycemia characteristic of the disease. Inhibitors of FBPase are expected to fulfill an unmet medical need because the majority of current antidiabetic medications act primarily on insulin resistance o